Publikationen in Zusammenarbeit mit Forschern von University of Ferrara (33)

2023

  1. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811

  2. Comparison of the Accuracy of the 7-Item HADS Depression Subscale and 14-Item Total HADS for Screening for Major Depression: A Systematic Review and Individual Participant Data Meta-Analysis

    Psychological Assessment, Vol. 35, Núm. 2, pp. 94-114

  3. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  4. Diagnosis and treatment of progressive multiple sclerosis: A position paper

    European Journal of Neurology, Vol. 30, Núm. 1, pp. 9-21

  5. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  6. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

    Clinical and experimental rheumatology, Vol. 41, Núm. 3, pp. 543-553

  7. Interventional Versus Conservative Strategy in Patients with Spontaneous Coronary Artery Dissections: Insights from DISCO Registry

    Circulation: Cardiovascular Interventions, Vol. 16, Núm. 6, pp. E012780

2022

  1. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

    Frontiers in Immunology, Vol. 13

  2. Multiple sclerosis in the era of COVID-19: Disease course, DMTs and SARS-CoV2 vaccinations

    Current Opinion in Neurology, Vol. 35, Núm. 3, pp. 319-327

  3. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial

    The Lancet. Respiratory medicine, Vol. 10, Núm. 5, pp. 435-446

  4. Prognostic significance of laterality in lung neuroendocrine tumors

    Endocrine, Vol. 76, Núm. 3, pp. 733-746

  5. Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide

    Frontiers in Immunology, Vol. 13

2021

  1. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study

    The Lancet Rheumatology, Vol. 3, Núm. 7, pp. e481-e488

  2. Variations in Quality of Care by Sex and Social Determinants of Health among Younger Adults with Acute Myocardial Infarction in the US and Canada

    JAMA Network Open, Vol. 4, Núm. 10

2020

  1. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464

  2. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

    Leukemia, Vol. 34, Núm. 9, pp. 2354-2363

  3. Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials

    European heart journal, Vol. 41, Núm. 42, pp. 4103-4110

  4. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study

    Cancer Medicine, Vol. 9, Núm. 22, pp. 8468-8479

  5. Nutritional status and all-cause mortality in older adults with acute coronary syndrome

    Clinical Nutrition, Vol. 39, Núm. 5, pp. 1572-1579

  6. Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial

    American Heart Journal, Vol. 229, pp. 100-109